Evidence map›Paper›PMID 36688680›Full record

ArticleMolecular oncology2023

Tetraploidy-linked sensitization to CENP-E inhibition in human cells.

Koya Yoshizawa, Akira Matsura, Masaya Shimada, Sumire Ishida-Ishihara, Fuyu Sato, Takahiro Yamamoto, Kan Yaguchi, Eiji Kawamoto, Taruho Kuroda, Kazuya Matsuo and 5 more

Open access · goldAbstract read
In one paragraph

Article in Molecular oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 2 countries.

Koya YoshizawaGraduate School of Life Science, Hokkaido University, Sapporo, Japan.ORCID 0000-0001-8863-1437
Akira MatsuraGraduate School of Life Science, Hokkaido University, Sapporo, Japan.
Masaya ShimadaGraduate School of Life Science, Hokkaido University, Sapporo, Japan.
Sumire Ishida-IshiharaGraduate School of Life Science, Hokkaido University, Sapporo, Japan.
Fuyu SatoGraduate School of Life Science, Hokkaido University, Sapporo, Japan.
Takahiro YamamotoGraduate School of Life Science, Hokkaido University, Sapporo, Japan.
Kan YaguchiGraduate School of Life Science, Hokkaido University, Sapporo, Japan.
Eiji KawamotoGraduate School of Medicine, Mie University, Tsu, Japan.
Taruho KurodaGraduate School of Medicine, Mie University, Tsu, Japan.
Kazuya MatsuoFaculty of Molecular Chemistry and Engineering, Kyoto Institute of Technology, Kyoto, Japan.
Nobuyuki TamaokiResearch Institute for Electronic Science, Hokkaido University, Sapporo, Japan.
Ryuichi SakaiGraduate School and Faculty of Fisheries Sciences, Hokkaido University, Sapporo, Japan.
Yasuhito ShimadaDepartment of Integrative Pharmacology, Mie University Graduate School of Medicine, Tsu, Japan.
Mithilesh MishraDepartment of Biological Sciences, Tata Institute of Fundamental Research, Mumbai, India.
Ryota UeharaGraduate School of Life Science, Hokkaido University, Sapporo, Japan.ORCID 0000-0001-8240-7928
Hokkaido University · JPMie University · JPHokkaido University of Science · JPKyoto Institute of Technology · JPTata Institute of Fundamental Research · IN

Funding

Daiichi Sankyo Foundation of Life ScienceHokkaido University-Hitachi Joint Cooperative Support Program for Education and ResearchJapan Society for the Promotion of Science JP19H03219Japan Society for the Promotion of Science JP19H05413Japan Society for the Promotion of Science JP19J12210Japan Society for the Promotion of Science JP19KK0181Japan Society for the Promotion of Science JP21K19244Japan Society for the Promotion of Science JP21K20737Japan Society for the Promotion of Science JPJSBP120193801The Kato Memorial Bioscience FoundationThe Nakatani FoundationThe Orange FoundationThe Princess Takamatsu Cancer Research Fundthe Sasakawa Scientific Research GrantThe Smoking Research Foundation
6 · The paper itself

Abstract

Tetraploidy is a hallmark of cancer cells, and tetraploidy-selective cell growth suppression is a potential strategy for targeted cancer therapy. However, how tetraploid cells differ from normal diploids in their sensitivity to anti-proliferative treatments remains largely unknown. In this study, we found that tetraploid cells are significantly more susceptible to inhibitors of a mitotic kinesin (CENP-E) than are diploids. Treatment with a CENP-E inhibitor preferentially diminished the tetraploid cell population in a diploid-tetraploid co-culture at optimum conditions. Live imaging revealed that a tetraploidy-linked increase in unsolvable chromosome misalignment caused substantially longer mitotic delay in tetraploids than in diploids upon moderate CENP-E inhibition. This time gap of mitotic arrest resulted in cohesion fatigue and subsequent cell death, specifically in tetraploids, leading to tetraploidy-selective cell growth suppression. In contrast, the microtubule-stabilizing compound paclitaxel caused tetraploidy-selective suppression through the aggravation of spindle multipolarization. We also found that treatment with a CENP-E inhibitor had superior generality to paclitaxel in its tetraploidy selectivity across a broader spectrum of cell lines. Our results highlight the unique properties of CENP-E inhibitors in tetraploidy-selective suppression and their potential use in the development of tetraploidy-targeting interventions in cancer.

Indexed as

Chromosomal Proteins, Non-HistoneNeoplasmsTetraploidyCell LineHumansMicrotubulesMitosisPaclitaxelcentromere protein EChromosomal Proteins, Non-HistonePaclitaxelchromosomemitosismotor proteinploidy

Identifiers

PMID36688680
PMCPMC10257419
OpenAlexW4317748823

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.